![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 4, 2479-2485, January 28, 2000
From the Shanghai Institute of Cell Biology, Chinese Academy of
Sciences, Shanghai 200031, People's Republic of China
The chemokine receptor CXCR4 has recently been
shown to be a co-receptor involved in the entry of human
immunodeficiency virus type 1 into target cells. This study shows that
coexpression of Chemokines are a large family of chemotactic proteins that
regulate leukocyte activation, recruitment to sites of inflammation, and many other immune responses (1). Four classes of chemokines have
been defined based on the arrangement of the conserved cysteine residues of the mature proteins (2, 3). Chemokines bind to a family of
G protein-coupled receptors
(GPCRs)1 that are
differentially and widely expressed in blood cells (4). The chemokine
receptors CCR5 and CXCR4 have recently been reported to act as major
co-receptors (along with CD4) involved in the entry of macrophage
tropic and T-cell tropic HIV-1 strains, respectively, into target cells
(5-10). In addition, CD4-independent infection by HIV-2 has also been
shown to be mediated by CXCR4 (11). Stromal cell-derived factor-1 Despite the increasingly prominent role of CXCR4 and SDF-1 Studies on CXCR4 in leukocytes have revealed that CXCR4, in response to
SDF-1 Constructs--
Human wild-type CXCR4 cDNA with an influenza
hemagglutinin (HA) epitope at the N terminus and human Transfection and Expression of cAMP Assay--
Cells were challenged with agonist in the
presence of 30 µM forskolin (Sigma) and 500 µM 1-methyl-3-isobutylxantine (Sigma) at 37 °C for 15 min. The reactions were terminated with 1 N perchloric acid
and neutralized with 2 N K2CO3. The
cAMP level of each sample was determined in duplicate using
radioimmunoassay as described previously (29). Data were averaged from
several independent measurements and calculated as follows: 100 × [cAMP(for+agonist) [35S]GTP Receptor Internalization--
Cells were challenged with or
without 10 nM SDF-1 ERK Phosphorylation and Western Blot Analysis--
Cells were
challenged with 10 nM SDF-1 Immunoprecipitation and Cross-linking Experiments--
The
immunoprecipitation experiment was performed as describe (27, 30). HEK
293 cells grown on a 60-mm culture dish were lysed in 0.8 ml of
immunoprecipitation buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.4% digitonin) containing protease
inhibitors on ice for 45 min. The lysate was centrifuged at 12,000 × g for 30 min, and the supernatants were incubated with
12CA5 monoclonal antibodies (0.5 µg) and protein A-Sepharose (Life
Technologies, Inc.) on ice for 4 h. After washing with
immunoprecipitation buffer, the immunocomplexes absorbed onto protein
A-Sepharose were eluted in SDS-polyacrylamide gel electrophoresis
sample buffer (50 mM Tris-HCl, pH 7.4, 2% SDS, 5%
2-mercaptoethanol, 10% glycerol, and 0.01% bromphenol blue), and the
presence of CXCR4 was detected by Western blot analysis using 12CA5
monoclonal antibodies.
The cross-linking was performed using disuccinimidyl suberate (Pierce)
following the manufacturer's instructions. In brief, HEK 293 cells
were suspended in phosphate-buffered saline containing 10 mM Hepes, pH 7.4, and stimulated with SDF-1 GST Pull-down Assay--
The GST pull-down experiment was
performed as described (31). GST and GST fusion proteins with the CXCR4
third loop (GST-TL) were expressed in Escherichia coli
BL21(DE3). GST fusion proteins with the CXCR4 C terminus (GST-C) were
expressed in HEK 293 cells due to protein degradation when expressed in
bacteria. All of the fusion proteins were purified using
glutathione-Sepharose 4B (Amersham Pharmacia Biotech) according to the
manufacturer's instructions. The cytosolic fractions from HEK 293 cells expressing Statistical Analysis--
Data were analyzed by Student's
t test for comparison of independent means, with pooled
estimates of common variances.
Previous studies on CXCR4 have revealed that signaling and
internalization of CXCR4 are regulated by
phosphorylation-dependent and -independent mechanisms,
respectively, and that truncation of the last 34 amino acids in the C
terminus of CXCR4 (CXCR4-T) causes total loss of phosphorylation of the
receptor (26). The current study was undertaken to test the possible
role of Activation of the chemokine receptor CXCR4 stimulates inhibitory G
proteins and subsequently inhibits adenylyl cyclase. Therefore, the
effects of
-Arrestin Differentially Regulates the Chemokine Receptor
CXCR4-mediated Signaling and Receptor Internalization, and This
Implicates Multiple Interaction Sites between
-Arrestin and
CXCR4*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-arrestin with CXCR4 in human embryonic kidney 293 cells attenuated chemokine-stimulated G protein activation and
inhibition of cAMP production. Truncation of the C-terminal 34 amino
acids of CXCR4 (CXCR4-T) abolished the effects of
-arrestin on
CXCR4/G protein signaling, indicating the functional interaction of the
receptor C terminus with
-arrestin. On the other hand, receptor
internalization and the subsequent activation of extracellular
signal-regulated kinases were significantly promoted by coexpression of
-arrestin with CXCR4, whereas the C-terminal truncation of CXCR4 did
not affect this regulation of
-arrestin, suggesting that
-arrestin can functionally interact with CXCR4 with or without the C
terminus. Moreover,
2V54D, the dominant inhibitory
mutant of
-arrestin 2, exerted no effects on CXCR4/G protein
signaling, but strongly influenced receptor internalization and
extracellular signal-regulated kinase activation. Further cross-linking
experiments demonstrated that
-arrestin as well as
2V54D could physically contact both CXCR4 and CXCR4-T.
Glutathione S-transferase pull-down assay showed that
-arrestin was able to bind efficiently in vitro to both the third intracellular loop and the 34-amino acid C terminus of CXCR4.
Taken together, our data clearly establish that
-arrestin can
effectively regulate different functions of CXCR4 and that this is
mediated through its distinct interactions with the C terminus and
other regions including the third loop of CXCR4.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(SDF-1
), a CXC chemokine, is a specific ligand for the chemokine
receptor CXCR4 (5, 12, 13) and was recently found be able to inhibit
CXCR4-mediated HIV-1 infection in vitro (14, 15).
in the
regulation of HIV infection, little is known about the regulation of
signal transduction of CXCR4. The classical mechanism of signal
transduction is based on the work of the
2-adrenergic receptor, a well studied model system of the GPCR superfamily. Upon
agonist stimulation, the receptors are phosphorylated by cAMP-dependent kinase A, protein kinase C, or G
protein-coupled receptor kinase (GRK), followed by binding of an
important regulator, arrestin. Arrestin proteins have been shown to
play important roles in the desensitization and internalization of the
2-adrenergic receptor and receptor-mediated activation
of extracellular signal-regulated kinase (ERK) (16-18). Up to date,
six members of the arrestin family have been cloned and characterized:
visual arrestin,
-arrestins 1 and 2, X-arrestin, D-arrestin, and
E-arrestin (19). Visual arrestin, which was originally named S-antigen,
is a highly pathogenic protein and is responsible for induction of
experimental autoimmune uveitis, a T-cell-mediated disease (20). Both
-arrestins are ubiquitously expressed, but are found with the
highest expression in nervous and lymphatic tissues (21), suggesting a
potential important role of
-arrestin in regulating the
physiological activity of leukocytes. Accumulating evidence has
indicated that
-arrestin is involved in signal transduction of other
chemokine receptors such as CXCR1 (22), CCR2B (23), and CCR5, another
intensively investigated HIV co-receptor (24).
, can mediate many signaling events such as inhibitory G
protein activation, receptor phosphorylation, internalization, inositol
phosphate generation, and ERK phosphorylation (25, 26). In this study,
we used the well established HEK 293 cell system to investigate the
regulation by
-arrestin of the signaling and internalization of
CXCR4. Our results demonstrate that
-arrestin effectively regulates
the different functions of CXCR4 and, more interestingly, that the
regulation by
-arrestin appears to be mediated via at least two
distinct interaction sites on CXCR4.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-arrestin 1 and 2 cDNA constructs were as described (27). The human HA-tagged
CXCR4-T (with a truncation of the C-terminal 34 amino acids of CXCR4) cDNA clone and
2V54D (the dominant inhibitory mutant
of
-arrestin 2 with valine 54 substituted by aspartic acid) cDNA
clone were constructed by polymerase chain reaction mutagenesis. All of
the above constructs were in pcDNA3 (Invitrogen). The sequence of the CXCR4 third intracellular loop subdomain (amino acids 219-243) was
generated by polymerase chain reaction and inserted into pGEX-4T1 (Amersham Pharmacia Biotech). The sequence of the GST-fused CXCR4 C-terminal (the last 34 amino acids in the C terminus) subdomain was
inserted into pcDNA3. Authenticity of sequences was confirmed by
DNA sequencing. SDF-1
was obtained from PeproTech (London, United Kingdom).
-Arrestin and Chemokine
Receptors--
HEK 293 cells (American Type Culture Collection) were
plated on 60-mm tissue culture dishes at 1 × 106
cells/dish in modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% heat-inactivated fetal bovine serum 20 h before transfection. Transfection was performed using 2.0 µg of chemokine receptor and 2.0 µg of
-arrestin cDNA/1 × 106 cells and the calcium phosphate-DNA coprecipitation
method as described (28). The total amount of DNA transfected was kept constant (4 µg of cDNA/1 × 106 cells) by
addition of pcDNA3. The cells were used 48 h
post-transfection. The level of chemokine receptor expression was
carefully controlled and monitored by flow cytometry or
immunoprecipitation and Western blot analysis. Expression of
-arrestin was monitored by Western blot analysis. The expression
levels of both the receptor and
-arrestin were kept consistent in
this study.
cAMP(basal)]/[cAMP(for)
cAMP(basal)], where cAMP(for+agonist) is cAMP
accumulation in the presence of forskolin and agonist, cAMP(basal) is in the absence of forskolin and agonist, and
cAMP(for) is in the presence of forskolin alone.
S Binding Assay--
The experiments
were performed as described previously (29). Cells were lysed in 5 mM Tris-HCl, pH 7.5, 5 mM EDTA, and 5 mM EGTA at 4 °C, and the lysate was centrifuged at
30,000 × g for 10 min. The membrane pellet was
resuspended, and an aliquot (8 µg of protein) was incubated at
30 °C for 1 h in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 100 mM NaCl, 40 µM GDP, and 8 nM [35S]GTP
S (1200 Ci/mmol; NEN Life Science Products) in
the presence or absence of agonist. The reaction was terminated by
dilution in cold phosphate-buffered saline and filtered through GF/C
filters under vacuum. Bound radioactivity was determined in duplicate by liquid scintillation spectrophotometry. Basal binding was determined in the absence of agonist, and nonspecific binding was determined in
the presence of 10 µM nonradioactive GTP
S. Data were
averaged from several independent measurements, and percentage of
stimulated [35S]GTP
S was calculated as follows:
100 × ((cpmsample
cpmnonspecific)/(cpmbasal
cpmnonspecific)).
in modified Eagle's medium
containing 0.1% bovine serum albumin at 37 °C for 30 min. After
treatment, cells were placed on ice and washed twice with
phosphate-buffered saline. The presence of HA-tagged chemokine
receptors on the cell surface was detected as described (27). The cells
were incubated with mouse monoclonal antibody 12CA5 (Roche Molecular
Biochemicals, Mannheim, Germany) against the influenza HA epitope (5 µg/ml) in phosphate-buffered saline containing 1% bovine serum
albumin at 4 °C for 2 h and then with fluorescein
isothiocyanate-conjugated goat anti-mouse IgG (Tago, Inc., Burlingame,
CA). The samples were analyzed on a FACSCalibur flow cytometer (Becton
Dickinson, Mountain View, CA). Basal cell fluorescence intensity was
determined with cells stained with the secondary antibody alone.
in modified Eagle's medium
containing 0.1% bovine serum albumin at 37 °C for 10 min. The cells
were then lysed in 10 mM Tris-HCl, pH 7.4, 5 mM
EDTA, 2% SDS, and 1% 2-mercaptoethanol. Aliquots (50 µg of protein) of the whole cell extracts prepared were subjected to 10%
SDS-polyacrylamide gel electrophoresis and then electroblotted onto
nitrocellulose membranes. The total amounts of ERK and phosphorylated
ERK were detected by anti-total p44/p42 mitogen-activated protein
kinase antibodies and anti-phospho-p44/p42 mitogen-activated protein kinase antibodies (New England Biolabs Inc.), respectively. Western blot results were quantified by densitometric scanning of x-ray films
using a Bio-Rad Model GS 700 imaging densitometer. Immunoblotting of
-arrestin and HA-tagged chemokine receptors and receptor fragments was performed using anti-
-arrestin polyclonal antibodies and mouse
12CA5 monoclonal antibodies against the influenza HA epitope, respectively.
(10 nM) at 37 °C for 15 min. The cells were then incubated
with disuccinimidyl suberate (0.1 mM) at room temperature
for 30 min in a total volume of 400 µl. The reaction was terminated
by addition of cold Tris-HCl, pH 7.4, to a final concentration of 10 mM and incubation for an additional 15 min. The samples
were analyzed by immunoprecipitation and Western blotting. The
cross-linked complex of
-arrestin and chemokine receptors was
detected by anti-
-arrestin antibodies.
-arrestin 2 and
2V54D were incubated
with ~5 µg of GST fusion proteins bound to the glutathione resin in
100 µl of buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM
phenylmethylsulfonyl fluoride for 1 h at 4 °C. The resin was
washed three times with 0.2 ml of the same buffer and then eluted with
SDS-polyacrylamide gel electrophoresis sample buffer and applied to a
denaturing 10% polyacrylamide gel. The proteins retained on the resin
were detected by anti-GST and anti-
-arrestin antibodies, respectively.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-arrestin in the signaling and internalization mediated by
CXCR4 or by the same truncated receptor (CXCR4-T) in HEK 293 cells.
Both receptors, with HA tags at their amino termini, were well
expressed on the cell surface as determined by fluorescence-activated
cell sorting using anti-HA 12CA5 monoclonal antibodies (Fig.
1A). Expression of CXCR4 and
CXCR4-T was further confirmed by Western blot analysis with 12CA5
monoclonal antibodies after immunoprecipitation of receptors from
plasma membranes of transfected HEK 293 cells, with apparent molecular
masses of ~44 kDa for CXCR4 and ~41 kDa for CXCR4-T (Fig.
1B). Western blot analysis was also used to show that
-arrestin is endogenously expressed in HEK 293 cells and that
transfection of
-arrestin 1 or 2 cDNA resulted in a 5-10-fold
increase in
-arrestin expression over the basal level (Fig.
1C). The expression levels of
-arrestin in cells
cotransfected with either receptor were kept comparable (data not
shown).

View larger version (24K):
[in a new window]
Fig. 1.
Expression of CXCR4 and CXCR-T in HEK 293 cells. A, flow cytometric analysis of surface
expression of receptors in pcDNA3-transfected HEK 293 cells
(dashed line) and in HEK 293 cells expressing HA-tagged
human CXCR4 (thick line) or CXCR4-T (thin line)
with anti-HA 12CA5 monoclonal antibodies and fluorescein
isothiocyanate-labeled goat anti-mouse antibodies; B,
Western blot analysis of immunoprecipitated receptors from cells
expressing CXCR4 (lane 1) or CXCR4-T (lane 2)
with anti-HA 12CA5 monoclonal antibodies as described under
"Experimental Procedures"; C, Western blot analysis of
expression of
-arrestins (
-arr) 1 (lane 2)
and 2 (lane 3) expressed in HEK 293 cells compared with
endogenous
-arrestin in pcDNA3-transfected cells (lane
1) with anti-
-arrestin antibodies. Data are representative of
several independent experiments.
-arrestin on the activation of the inhibitory G proteins
stimulated by SDF-1
were examined using the
[35S]GTP
S binding assay and the cAMP assay in cells
coexpressing
-arrestin and CXCR4. It was shown that SDF-1
stimulated [35S]GTP
S binding to cell membranes (Fig.
2A) and inhibited cellular cAMP production (Fig. 2B) in cells expressing exogenous
CXCR4. The CXCR4-mediated G protein activation was strongly attenuated by coexpression of either
-arrestin in a dose-dependent
manner (Fig. 2A), with a 50% inhibition at 10 nM SDF-1
(p < 0.01), suggesting that
more rapid clearance of the receptor from the membrane would reduce the
response of the ligand with regard to GTP binding. Cotransfection of
either
-arrestin with CXCR4 also significantly attenuated
SDF-1
-induced inhibition of cellular cAMP production (Fig.
2B). In both assays, the SDF-1
concentration-response
curves were shifted to the right, and the EC50 values for
SDF-1
were increased 10-fold in cells cotransfected with
-arrestin and CXCR4 as compared with those in cells expressing CXCR4
alone (Fig. 2, A and B). These data clearly
indicate that
-arrestin plays a significant role in the regulation
of CXCR4/G protein coupling and subsequent G protein-mediated
downstream signaling.

View larger version (26K):
[in a new window]
Fig. 2.
Effects of
-arrestin
on CXCR4-mediated G protein activation. A, membrane
preparations of HEK 293 cells cotransfected with CXCR4 plus pcDNA3
or
-arrestin (
-arr) 1 or 2 cDNA were incubated
with SDF-1
at the concentrations indicated at 30 °C for 60 min,
and [35S]GTP
S binding to membranes was determined.
B, HEK 293 cells cotransfected with CXCR4 plus pcDNA3 or
-arrestin 1 or 2 cDNA were incubated with SDF-1
at the
concentrations indicated at 37 °C for 15 min, and cAMP accumulation
was determined. Data are means ± S.E. of at least three
independent experiments.
To investigate the effect of cotransfected
-arrestin on CXCR4
internalization in HEK 293 cells, we measured CXCR4 internalization following a 30-min exposure to 10 nM SDF-1
by flow
cytometry after fluorescence staining of the cell-surface receptor with 12CA5 monoclonal antibodies (Fig.
3A). When expressed alone in HEK 293 cells, CXCR4 was internalized ~20%. Internalization of the
receptor was modestly enhanced by coexpression of
-arrestin 1, but
was significantly increased up to ~40% by coexpression of
-arrestin 2 (Fig. 3A). Moreover, cotransfection of
-arrestin 1 or 2 with a G protein-coupled receptor kinase (GRK2)
produced a synergistic increase in CXCR4 internalization, indicating
that
-arrestin-enhanced CXCR4 internalization can be facilitated by GRK phosphorylation. The function of
-arrestin in CXCR4-mediated ERK
activation was also investigated (Fig. 3B). It has been
reported that SDF-1
treatment can activate ERK via CXCR4 (25). Our
results show that a 10-min exposure to SDF-1
led to an increase in
ERK phosphorylation ~3-4-fold above the control level (without
SDF-1
stimulation) in cells transfected with CXCR4 (Fig.
3B). Under such conditions, coexpression of either
-arrestin resulted in a dramatic increase in SDF-1
-induced ERK
phosphorylation to ~6-7-fold above the control level (Fig.
3B), whereas the basal expression of ERK was unchanged in
the same cells (data not shown). Thus, in contrast to the negative
regulation by
-arrestin of CXCR4-mediated G protein activation,
-arrestin exerted a remarkably positive effect on CXCR4
internalization and receptor-mediated ERK activation.
|
The third intracellular loop and carboxyl terminus have previously been
implicated in GPCR interaction with cytosolic proteins such as GRK and
arrestin (31-36). It has recently been demonstrated that truncation at
different sites in the CXCR4 C terminus causes total loss of receptor
phosphorylation, desensitization, and internalization (25, 37). To
access the contribution of the C terminus of CXCR4 to the regulation by
-arrestin of receptor responsiveness, CXCR4-T (with the
carboxyl-terminal 34 amino acids removed) was constructed. The results
show that truncation of the CXCR4 C terminus strongly attenuated
interference of
-arrestin with both SDF-1
-stimulated activation
of G proteins and inhibition of adenylyl cyclase (Fig. 4, A and B), which
indicated that the C-terminal structure of CXCR4 is crucial for
-arrestin to regulate receptor/G protein coupling. In contrast, the
same truncation of the CXCR4 C terminus did not significantly affect
the enhancement role of
-arrestin in SDF-1
-stimulated receptor
internalization and ERK activation (Fig.
5, A and B). This
suggests that the C-terminal domain of CXCR4 is not essential for
-arrestin to regulate receptor internalization, and it also implies
that some regions of CXCR4 other than the C terminus would be subject
to this regulation.
|
|
The
-arrestin 2 mutant
2V54D is known to prevent GPCR
targeting to clathrin-coated pits and subsequently to inhibit
internalization of GPCRs (17). The current study revealed that
coexpression of
2V54D exhibited little effect on the
receptor signaling of CXCR4 or CXCR4-T (Fig. 4, A and
B), but dramatically decreased SDF-1
-stimulated
internalization of both receptors (Fig. 5A). Coexpression of
2V54D also significantly impaired SDF-1
-induced ERK
activation by 40 and 50% in cells expressing CXCR4 and CXCR4-T, respectively (Fig. 5B), indicating a critical role of
-arrestin-promoted CXCR4 internalization in ERK activation, as in
the case of the
2-adrenergic receptor. Our data thus
demonstrate that
-arrestin regulation of two important signaling
functions of CXCR4, namely G protein activation and receptor
internalization, is mediated by at least two distinct interactions
since the CXCR4/
-arrestin interactions can be separately disrupted
by the mutation of either the receptor (CXCR4-T) or
-arrestin
(
2V54D).
The direct physiological interaction between
-arrestin and CXCR4 was
further accessed using a cross-linking assay that has been successfully
applied in the study of the
2-adrenergic receptor (18).
When coexpressed with CXCR4 in HEK 293 cells, either
-arrestin 2 or
2V54D could be coprecipitated with the HA-tagged
receptor after exposure of the cells to SDF-1
and the covalent
cross-linking agent (Fig. 6A).
Both arrestins were also shown to be cross-linked to CXCR4-T in an
agonist-dependent manner (Fig. 6B) at even
higher levels compared with wild-type CXCR4. Our data indicate that
-arrestin can effectively interact with CXCR4 whether the C terminus
of the receptor is present or not, thus further supporting the
existence of multifunctional interactions via at least two distinct
sites between
-arrestin and CXCR4.
|
To define the concrete sites on CXCR4 contributing to its interaction
with
-arrestin, a GST pull-down assay was employed. The results show
that
-arrestin 2 expressed in HEK 293 cells bound effectively to
both GST-C and GST-TL fusion proteins, but not to the control GST
proteins (Fig. 7). Interestingly, the
-arrestin 2 mutant
2V54D interacted with GST-TL as
efficiently as its wild-type counterpart, whereas it bound much less to
GST-C compared with wild-type
-arrestin. The lack of interaction of
2V54D with GST-C in this assay agreed well with the
results showing that the
-arrestin 2 mutant did not affect CXCR4
signaling and that it blocked the receptor internalization of both
CXCR4 receptors with or without the C terminus. Thus, our data provide
clear evidence that
-arrestin can directly interact with the
chemokine receptor CXCR4 via at least two distinct sites, the third
loop domain and the C terminus, and that different interactions of
-arrestin with CXCR4 play differential functional roles in the
regulation of CXCR4 by
-arrestin.
|
| |
DISCUSSION |
|---|
|
|
|---|
Although it has been reported that
-arrestin can functionally
regulate many chemokine receptors such as CCR5, CCR2B, and CXCR1 (23,
24), it was not known until this study was performed whether
-arrestin could play similar functional roles in CXCR4 signal
transduction. Our results have demonstrated that
-arrestin is
critically involved in the regulation of the most studied signal pathways mediated by CXCR4, a chemokine receptor of considerable interest due to its role as both chemoattractant receptor and HIV
co-receptor. Since CXCR4 is wildly expressed in human blood neutrophils
and lymphocytes (38), in which
-arrestin expression is also very
high (21), the functional regulation of CXCR4 by
-arrestin, as
revealed by this study, should play an important role in CXCR4- and
other chemokine receptor-mediated immunological responses. Moreover, it
can be reasonably speculated that
-arrestin may be also functionally
involved in the process of HIV infection due to its regulation of the
two HIV co-receptors, CXCR4 and CCR5 (24).
It has been reported that truncation of the C terminus of CXCR4 leads
to higher receptor-mediated activities in inositol phosphate formation
and in the induction of sustained calcium fluxes as compared with
wild-type CXCR4 (26). It has been suggested that these phenomena are
due to loss of down-regulatory control to the mutant receptor. The
current results that
-arrestin can effectively regulate CXCR4/G
protein signaling of CXCR4, but not that of CXCR4-T, indicate that the
inhibitory regulation of CXCR4 by
-arrestin could be the
hypothesized down-regulatory control and partly explain the previous observation.
For most members of the GPCR family, agonist-stimulated phosphorylation
of GPCR occurs at serine and threonine in the intracellular domains of
the C terminus and/or the third intracellular loop (32-35, 39, 40).
The cytoplasmic tail of CXCR4 contains 18 serine/threonine residues,
among the highest in the chemokine receptors. Truncation of its C
terminus is reported to cause nearly total loss of receptor
phosphorylation in rat basophilic leukemia cells stably expressing
CXCR4 while producing no change in CXCR4 internalization (26). The
current study reveals that
-arrestin significantly augments
SDF-1
-induced internalization of both CXCR4 and CXCR4-T in HEK 293 cells, indicating that the regulation of receptor internalization by
-arrestin is not critically dependent on phosphorylation of the
receptor C terminus. Of interest, the synergistic increase in receptor
internalization by coexpression of
-arrestin with GRK2 shown in this
report for CXCR4 and in an earlier study for CCR5 (24) implies that
chemokine receptor internalization can be facilitated by GRK at least
under the conditions of overexpression. It has demonstrated that CXCR4
undergoes significant spontaneous endocytosis and that recycling of
internalized receptors is not efficient (41). Our data show that
overexpression of
-arrestin exerted little effect on CXCR4
spontaneous endocytosis while remarkably increasing receptor recycling
to the membrane (data not shown). Further study to investigate the role
of
-arrestin in CXCR4 internalization and recycling is to be continued.
The dominant inhibitory mutant of
-arrestin 2 (
2V54D)
is known to prevent GPCR targeting to clathrin-coated pits and
subsequent receptor internalization (17). In the current study,
overexpression of the same
-arrestin 2 mutant led to a dramatic
decrease in SDF-1
-induced internalization of both CXCR4 and CXCR4-T.
SDF-1
-stimulated phosphorylation of ERK via both receptors was also
inhibited by
2V54D. Taken together, our data demonstrate
that
-arrestin-facilitated receptor internalization plays a crucial
role in CXCR4-mediated ERK activation, as in the well known case of the
2-adrenergic receptor (18, 42). It has been demonstrated
that opioid-mediated ERK activation is not dependent on
-opioid
receptor internalization (43), suggesting that receptor
internalization-dependent ERK activation may not be
universal and may have some receptor specificity. It is also worth
noting that
-arrestin 2 induced a more robust increase in CXCR4
internalization than did
-arrestin 1, although they appeared equal
in enhancing CXCR4-mediated ERK activation. However,
-arrestins 1 and 2 were equivalent in the regulation of CXCR4 internalization in the
presence of overexpressed GRK2, suggesting that regulation by
-arrestin 1 more likely depends on CXCR4 phosphorylation.
-Arrestin has been reported to interact with GPCRs at their third
intracellular loop (31) or C terminus (36, 44), according to the
localization of relevant phosphorylation sites and the sizes and amino
acid sequences of both domains (45). However, no evidence has emerged
that
-arrestin can functionally interact at two distinct domains of
GPCRs simultaneously. This study has demonstrated that
-arrestin
efficiently interferes with both receptor/G protein coupling, which is
mediated by the CXCR4 C terminus, and receptor internalization, which
is independent of the C terminus. The regulation of CXCR4
internalization by
-arrestin seems likely to be mediated by its
interaction with the third intracellular loop and/or other
intracellular domain(s) such as the second loop of the receptor. Our
results from in vivo cross-linking and in vitro
GST pull-down assays provide direct evidence of a physical interaction
between
-arrestin and two distinct sites of CXCR4, namely the C
terminus and the third intracellular loop. Moreover, this study further
establishes that the distinct interaction of
-arrestin with
different domains of CXCR4 produces the differential regulation of
receptor functions by
-arrestin. Thus, it is feasible both in theory
and in practice to block or to enhance one of the regulatory functions
of
-arrestin for receptors by purposely modifying the structures of
-arrestin or the receptors it regulates.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Shunmei Xin, Professor Yaling Huang, XuMing Zhang, and PeiHua Wu for assistance and Dr. Lan Ma for helpful discussion. We especially thank Dr. Kun Ling for technical expertise and helpful discussion.
| |
FOOTNOTES |
|---|
* This work was supported by National Natural Science Foundation of China Research Grants 39630130 and 39625015, Chinese Academy of Sciences Research Grants KJ951-B1-608 and KY951-A1-301, and research grants from the Shanghai Research Center of Life Sciences and the German Max Planck Society.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Shanghai Inst. of Cell
Biology, 320 Yue Yang Rd., Shanghai 200031, People's Republic of
China. Tel.: 21-6471-6049; Fax: 21-6471-8563; E-mail:
gangpei@sunm.shcnc.ac.cn.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
GPCRs, G
protein-coupled receptors;
HIV, human immunodeficiency virus;
SDF-1
, stromal cell-derived factor-1
;
GRK, G protein-coupled receptor
kinase;
ERK, extracellular signal-regulated kinase;
HEK, human
embryonic kidney;
HA, hemagglutinin;
CXCR4-T, truncated CXCR4;
GST, glutathione S-transferase;
GTP
S, 5'-3-O-(thiotriphosphate).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Murphy, P. M. (1994) Annu. Rev. Immunol. 12, 593-633[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., and Schall, T. J. (1997) Nature 385, 640-644[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Kelner, G. S.,
Kennedy, J.,
Bacon, K. B.,
Kleyensteuber, S.,
Largaespada, D. A.,
Jenkins, N. A.,
Copeland, N. G.,
Bazan, J. F.,
Moore, K. W.,
and Schall, T. J.
(1994)
Science
266,
1395-1399 |
| 4. | Power, C. A., and Wells, T. N. (1996) Trends Pharmacol. Sci. 17, 209-213[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996) Science 272, 872-877[Abstract] |
| 6. | Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C., and Sodroski, J. (1996) Cell 85, 1135-1148[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., and Doms, R. W. (1996) Cell 85, 1149-1158[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996) Nature 381, 661-666[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., and Berger, E. A. (1996) Science 272, 1955-1958[Abstract] |
| 10. | Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton, W. A. (1996) Nature 381, 667-673[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Endres, M. J., Clapham, P. R., Marsh, M., Ahuja, M., Turner, J. D., McKnight, A., Thomas, J. F., Stoebenau-Haggarty, B., Choe, S., Vance, P. J., Wells, T. N., Power, C. A., Sutterwala, S., Doms, R. W., Landau, N. R., and Hoxie, J. A. (1996) Cell 87, 745-756[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark, L. I., Sodroski, J., and Springer, T. A. (1996) Nature 382, 829-833[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J. L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J. M., Clark-Lewis, I., Legler, D. F., Loetscher, M., Baggiolini, M., and Moser, B. (1996) Nature 382, 833-835[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Ueda, H.,
Siani, M. A.,
Gong, W.,
Thompson, D. A.,
Brown, G. G.,
and Wang, J. M.
(1997)
J. Biol. Chem.
272,
24966-24970 |
| 15. |
Murakami, T.,
Nakajima, T.,
Koyanagi, Y.,
Tachibana, K.,
Fujii, N.,
Tamamura, H.,
Yoshida, N.,
Waki, M.,
Matsumoto, A.,
Yoshie, O.,
Kishimoto, T.,
Yamamoto, N.,
and Nagasawa, T.
(1997)
J. Exp. Med
186,
1389-1393 |
| 16. |
Pippig, S.,
Andexinger, S.,
Daniel, K.,
Puzicha, M.,
Caron, M. G.,
Lefkowitz, R. J.,
and Lohse, M. J.
(1993)
J. Biol. Chem.
268,
3201-3208 |
| 17. | Ferguson, S. S., Downey, W. E., III, Colapietro, A. M., Barak, L. S., Menard, L., and Caron, M. G. (1996) Science 271, 363-366[Abstract] |
| 18. |
Luttrell, L. M.,
Ferguson, S. S.,
Daaka, Y.,
Miller, W. E.,
Maudsley, S.,
Della Rocca, G. J.,
Lin, F.,
Kawakatsu, H.,
Owada, K.,
Luttrell, D. K.,
Caron, M. G.,
and Lefkowitz, R. J.
(1999)
Science
283,
655-661 |
| 19. | Ferguson, S. S., Barak, L. S., Zhang, J., and Caron, M. G. (1996) Can. J. Physiol. Pharmacol. 74, 1095-1110[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Mochizuki, M.,
Nussenblatt, R. B.,
Kuwabara, T.,
and Gery, I.
(1985)
Invest. Ophthalmol. Visual Sci.
26,
226-232 |
| 21. | Parruti, G., Lombardi, M. S., Chuang, T. T., and De Blasi, A. (1993) J. Recept. Res. 13, 95-103[Medline] [Order article via Infotrieve] |
| 22. |
Barlic, J.,
Khandaker, M. H.,
Mahon, E.,
Andrews, J.,
DeVries, M. E.,
Mitchell, G. B.,
Rahimpour, R.,
Tan, C. M.,
Ferguson, S. S. G,
and Kelvin, D. J.
(1999)
J. Biol. Chem.
274,
16287-16294 |
| 23. |
Aragay, A. M.,
Mellado, M.,
Frade, J. M.,
Martin, A. M.,
Jimenez-Sainz, M. C., A.,
Martinez-C,
and Mayor, F., Jr.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2985-2990 |
| 24. | Aramori, I., Ferguson, S. S., Bieniasz, P. D., Zhang, J., Cullen, B., and Cullen, M. G. (1997) EMBO. J. 16, 4606-4616[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Ganju, R. K.,
Brubaker, S. A.,
Meyer, J.,
Dutt, P.,
Yang, Y.,
Qin, S.,
Newman, W.,
and Groopman, J. E.
(1998)
J. Biol. Chem.
273,
23169-23175 |
| 26. |
Haribabu, B.,
Richardson, R. M.,
Fisher, I.,
Sozzani, S.,
Peiper, S. C.,
Horuk, R.,
Ali, H.,
and Snyderman, R.
(1997)
J. Biol. Chem.
272,
28726-28731 |
| 27. |
Ling, K.,
Wang, P.,
Zhao, J.,
Wu, Y. L.,
Cheng, Z. J.,
Wu, G. X.,
Hu, W.,
Ma, L.,
and Pei, G.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7922-7927 |
| 28. |
Didsbury, J.,
Uhing, R.,
Tomhave, E.,
Gerard, C.,
Gerard, N.,
and Snyderman, R.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
11564-11568 |
| 29. | Cheng, Z. J., Fan, G. H., Zhao, J., Zhang, Z., Wu, Y. L., Jiang, L. Z., Zhu, Y., Pei, G., and Ma, L. (1997) Neuroreport 8, 1913-1918[Medline] [Order article via Infotrieve] |
| 30. |
Zhao, J.,
Ben, L. H.,
Wu, Y. L.,
Hu, W.,
Ling, K.,
Xin, S. M.,
Nie, H. L.,
Ma, L.,
and Pei, G.
(1999)
J. Exp. Med.
190,
101-111 |
| 31. |
Wu, G.,
Krupnick, J. G.,
Benovic, J. L.,
and Lanier, S. M.
(1997)
J. Biol. Chem.
272,
17836-17842 |
| 32. | Benovic, J. L., Onorato, J., Lohse, M. J., Dohlman, H. G., Staniszewski, C., Caron, M. G., and Lefkowitz, R. J. (1990) Br. J. Clin. Pharmacol. 1, 3S-12S |
| 33. |
Palczewski, K.,
Buczylko, J.,
Kaplan, M. W.,
Polans, A. S.,
and Crabb, J. W.
(1991)
J. Biol. Chem.
266,
12949-12955 |
| 34. |
Chen, C. Y.,
Dion, S. B.,
Kim, C. M.,
and Benovic, J. L.
(1993)
J. Biol. Chem.
268,
7825-7831 |
| 35. |
Haga, K.,
Kameyama, K.,
and Haga, T.
(1994)
J. Biol. Chem.
269,
12594-12599 |
| 36. |
Krupnick, J. G.,
Gurevich, V. V.,
Schepers, T.,
Hamm, H. E.,
and Benovic, J. L.
(1994)
J. Biol. Chem.
269,
3226-3232 |
| 37. |
Signoret, N.,
Oldridge, J.,
Pelchen-Matthews, A.,
Klasse, P. J.,
Tran, T.,
Brass, L. F.,
Rosenkilde, M. M.,
Schwartz, T. W.,
Holmes, W.,
Dallas, W.,
Luther, M. A.,
Wells, T. N.,
Hoxie, J. A.,
and Marsh, M.
(1997)
J. Cell Biol.
139,
651-664 |
| 38. |
Loetscher, M.,
Geiser, T.,
O'Reilly, T.,
Zwahlen, R.,
Baggiolini, M.,
and Moser, B.
(1994)
J. Biol. Chem.
269,
232-237 |
| 39. | Sterne-Marr, R., and Benovic, J. L (1995) Vitam. Horm. 51, 193-234[Medline] [Order article via Infotrieve] |
| 40. | Freedman, N. J., and Lefkowitz, R. J (1996) Recent Prog. Horm. Res. 51, 319-351 |
| 41. |
Tarasova, N. I.,
Stauer, R. H.,
and Michejda, C. J.
(1998)
J. Biol. Chem.
273,
15883-15886 |
| 42. |
Daaka, Y.,
Luttrell, L. M.,
Ahn, S.,
Della Rocca, G. J.,
Ferguson, S. S.,
Caron, M. G.,
and Lefkowitz, R. J.
(1998)
J. Biol. Chem.
273,
685-688 |
| 43. |
Li, J.-G.,
Luo, L.-Y.,
Drupnick, J. G.,
Benovic, J. L.,
and Liu-Chen, L.-Y.
(1999)
J. Biol. Chem.
274,
12087-12094 |
| 44. |
Cheng, Z.-J., Yu, Q.-M.,
Wu, Y.-L.,
Ma, L.,
and Pei, G.
(1998)
J. Biol. Chem.
273,
24328-24333 |
| 45. | Probst, W. C., Snyder, L. A., Schuster, D. I., Brosius, J., and Sealfon, S. C. (1992) DNA Cell Biol. 11, 1-20[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
B. Lagane, K. Y. C. Chow, K. Balabanian, A. Levoye, J. Harriague, T. Planchenault, F. Baleux, N. Gunera-Saad, F. Arenzana-Seisdedos, and F. Bachelerie CXCR4 dimerization and {beta}-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome Blood, July 1, 2008; 112(1): 34 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. McCulloch, V. Morrow, S. Milasta, I. Comerford, G. Milligan, G. J. Graham, N. W. Isaacs, and R. J. B. Nibbs Multiple Roles for the C-terminal Tail of the Chemokine Scavenger D6 J. Biol. Chem., March 21, 2008; 283(12): 7972 - 7982. [Abstract] [Full Text] [PDF] |